MedTrace Logo

Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)

NCT04130204 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 284

Last updated 2022-05-13

No results posted yet for this study

Summary

This overall goal of this trial will be to demonstrate that DYV700 is safe and effective as a treatment for acute gout flares.

Conditions

Interventions

DRUG

DYV700

Proprietary transdermal delivery platform

DRUG

Placebo

Vehicle transdermal delivery platform

DRUG

Colchicine 0.6 mg

Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.

Sponsors & Collaborators

  • Dyve Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-12
Primary Completion
2021-05-21
Completion
2021-05-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04130204 on ClinicalTrials.gov